Revised Guidance Document on Developing and Assessing Adverse Outcome Pathways

JT03338300 Complete document available on OLIS in its original format This document and any map included herein are without prejudice to the status of or sovereignty over any territory, to the delimitation of international frontiers and boundaries and to the name of any territory, city or area. ABOUT THE OECD The Organisation for Economic Cooperation and Development (OECD) is an intergovernmental organisation in which representatives of 34 industrialised countries in North and South America, Europe and the Asia and Pacific region, as well as the European Commission, meet to coordinate and harmonise policies, discuss issues of mutual concern, and work together to respond to international problems. Most of the OECD's work is carried out by more than 200 specialised committees and working groups composed of member country delegates. Observers from several countries with special status at the OECD, and from interested international organisations, attend many of the OECD's workshops and other meetings. Committees and working groups are served by the OECD Secretariat, located in Paris, France, which is organised into directorates and divisions. This publication was developed in the IOMC context. The contents do not necessarily reflect the views or stated policies of individual IOMC Participating Organizations. The Inter-Organisation Programme for the Sound Management of Chemicals (IOMC) was established in 1995 following recommendations made by the 1992 UN Conference on Environment and Development to strengthen cooperation and increase international coordination in the field of chemical safety. The purpose of the IOMC is to promote coordination of the policies and activities pursued by the Participating Organisations, jointly or separately, to achieve the sound management of chemicals in relation to human health and the environment. ENV/JM/MONO(2013)6 6 FOREWORD The Adverse Outcome Pathway (AOP) methodology is an approach which provides a framework to collect, organise and evaluate relevant information on chemical, biological and toxicological effect of chemicals. This approach supports the use of a mode (and/or mechanism) of action basis for understanding adverse effects of chemicals. This guidance document intends to provide an insight into which pieces of information are necessary to identify and document an AOP and how to present them. It also provides initial assistance on how to undertake the assessment of an AOP in terms of its relevance and adequacy. A template has been included allowing authors to develop thorough AOPs and to improve consistency in AOPs developed by different stakeholders. The document also briefly outlines the potential use for …

[1]  M E Meek,et al.  New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis , 2013, Journal of applied toxicology : JAT.

[2]  Daniel L Villeneuve,et al.  Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment , 2010, Environmental toxicology and chemistry.

[3]  Igor Linkov,et al.  Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence. , 2015, Regulatory toxicology and pharmacology : RTP.

[4]  Jennifer Seed,et al.  Overview: Using Mode of Action and Life Stage Information to Evaluate the Human Relevance of Animal Toxicity Data , 2005, Critical reviews in toxicology.

[5]  B Alex Merrick,et al.  Genomic and proteomic profiling for biomarkers and signature profiles of toxicity. , 2004, Current opinion in molecular therapeutics.

[6]  M T D Cronin,et al.  A review of the electrophilic reaction chemistry involved in covalent DNA binding , 2010, Critical reviews in toxicology.

[7]  TG 442D OECD GUIDELINE FOR THE TESTING OF CHEMICALS In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method , 2000 .

[8]  Carolyn Vickers,et al.  Risk assessment of combined exposure to multiple chemicals: A WHO/IPCS framework. , 2011, Regulatory toxicology and pharmacology : RTP.

[9]  D. Weed Weight of Evidence: A Review of Concept and Methods , 2005, Risk analysis : an official publication of the Society for Risk Analysis.

[10]  Leroy Hood,et al.  The impact of systems approaches on biological problems in drug discovery , 2004, Nature Biotechnology.

[11]  Jennifer Seed,et al.  A Framework for Human Relevance Analysis of Information on Carcinogenic Modes of Action , 2003, Critical reviews in toxicology.

[12]  Scott D. Kahn,et al.  Current Status of Methods for Defining the Applicability Domain of (Quantitative) Structure-Activity Relationships , 2005, Alternatives to laboratory animals : ATLA.

[13]  Carolyn Vickers,et al.  IPCS framework for analysing the relevance of a cancer mode of action for humans , 2006 .

[14]  Francesco Falciani,et al.  Adverse Outcome Pathways for Regulatory Applications: Examination of Four Case Studies With Different Degrees of Completeness and Scientific Confidence. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[15]  W Steiling,et al.  Percutaneous penetration/dermal absorption of hair dyes in vitro. , 2001, Toxicology in vitro : an international journal published in association with BIBRA.

[16]  Nancy G Doerrer,et al.  Identification and characterization of adverse effects in 21st century toxicology. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[17]  Andrew Worth,et al.  Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA). , 2014, Regulatory toxicology and pharmacology : RTP.

[18]  A. B. Hill The Environment and Disease: Association or Causation? , 1965, Proceedings of the Royal Society of Medicine.

[19]  M Younes,et al.  IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. , 2001, Regulatory toxicology and pharmacology : RTP.

[20]  R Jeffrey Lewis,et al.  Mode of action human relevance (species concordance) framework: Evolution of the Bradford Hill considerations and comparative analysis of weight of evidence , 2014, Journal of applied toxicology : JAT.

[21]  Alan R. Boobis,et al.  IPCS Framework for Analyzing the Relevance of a Noncancer Mode of Action for Humans , 2008, Critical reviews in toxicology.

[22]  Sharon Munn,et al.  Adverse outcome pathway development II: best practices. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[23]  Florian Nigsch,et al.  Computational toxicology: an overview of the sources of data and of modelling methods. , 2009, Expert opinion on drug metabolism & toxicology.

[24]  Hugh A Barton,et al.  The Acquisition and Application of Absorption, Distribution, Metabolism, and Excretion (ADME) Data in Agricultural Chemical Safety Assessments , 2006, Critical reviews in toxicology.

[25]  R. Kavlock,et al.  Biological modeling of 5-fluorouracil developmental toxicity. , 1995, Toxicology.

[26]  Nicole C. Kleinstreuer,et al.  Disruption of embryonic vascular development in predictive toxicology. , 2011, Birth defects research. Part C, Embryo today : reviews.

[27]  Steven K. Gibb Toxicity testing in the 21st century: a vision and a strategy. , 2008, Reproductive toxicology.

[28]  Melvin E. Andersen,et al.  New directions in toxicity testing. , 2011, Annual review of public health.

[29]  Stefan Scholz,et al.  Adverse outcome pathways during early fish development: a conceptual framework for identification of chemical screening and prioritization strategies. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[30]  Daniel L Villeneuve,et al.  Vision & strategy: Predictive ecotoxicology in the 21st century , 2011, Environmental toxicology and chemistry.

[31]  H J Clewell,et al.  Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: examples with vinyl chloride and trichloroethylene. , 1995, Chemosphere.

[32]  Cheryl A Murphy,et al.  Adverse outcome pathways and ecological risk assessment: Bridging to population‐level effects , 2011, Environmental toxicology and chemistry.

[33]  REPORT OF THE WORKSHOP ON A FRAMEWORK FOR THE DEVELOPMENT AND USE OF INTEGRATED APPROACHES TO TESTING AND ASSESSMENT Environment Directorate ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT , 2015 .

[34]  J. Haines,et al.  International programme on chemical safety , 1996, The Lancet.

[35]  Melvin E Andersen,et al.  Defining and modeling known adverse outcome pathways: Domoic acid and neuronal signaling as a case study , 2011, Environmental toxicology and chemistry.

[36]  John H. Duffus,et al.  Appendix B: Glossary of Terms Used in Toxicology , 2006 .

[37]  R. Huggett,et al.  Biomarkers: Biochemical, Physiological, and Histological Markers of Anthropogenic Stress , 1992 .

[38]  Dries Knapen,et al.  The potential of AOP networks for reproductive and developmental toxicity assay development. , 2015, Reproductive toxicology.

[39]  T. W. Schultz Chapter 14:Adverse Outcome Pathways: A Way of Linking Chemical Structure to In Vivo Toxicological Hazards , 2010 .

[40]  A. B. Hill,et al.  "The Environment and Disease: Association or Causation?" (1965), by Austin Bradford Hill , 2017 .

[41]  Stephen W. Edwards,et al.  Reverse engineering adverse outcome pathways , 2011, Environmental toxicology and chemistry.

[42]  Robert J Kavlock,et al.  Computational toxicology--a state of the science mini review. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[43]  Melvin E. Andersen,et al.  The Future of Toxicity Testing , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.

[44]  Sharon Munn,et al.  Adverse outcome pathway (AOP) development I: strategies and principles. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[45]  U. Epa Guidelines for carcinogen risk assessment , 1986 .

[46]  James R Wheeler,et al.  Species extrapolation for the 21st century , 2011, Environmental toxicology and chemistry.

[47]  Richard A Becker,et al.  Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes. , 2015, Regulatory toxicology and pharmacology : RTP.

[48]  Robert Landsiedel,et al.  Intralaboratory validation of four in vitro assays for the prediction of the skin sensitizing potential of chemicals. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.